Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

This study tests a new treatment combination: CJRB-101 (a live bacterial product) plus pembrolizumab (an immunotherapy) in people with advanced lung cancer (NSCLC), head and neck cancer (HNSCC), or melanoma. CJRB-101 is designed to improve how well the immune system responds to immunotherapy. **You may be eligible if...** - You are 18 or older with confirmed NSCLC, HNSCC, or melanoma that has spread or cannot be removed by surgery - For newly diagnosed patients: NSCLC tumors must have no EGFR/ALK mutations and have high PD-L1 expression; HNSCC must have high PD-L1; melanoma patients qualify regardless of PD-L1 - For previously treated patients: You have had at least 2 cycles of a checkpoint inhibitor and your cancer has progressed, and you have had fewer than 3 prior lines of treatment - Your health status is good (ECOG 0–1) **You may NOT be eligible if...** - You have active autoimmune disease, HIV, hepatitis B or C, or inflammatory bowel disease - You have received a fecal transplant - You are pregnant or breastfeeding - You have active lung inflammation (ILD/pneumonitis) - You are allergic to clindamycin, erythromycin, or ampicillin - You have untreated brain metastases Talk to your doctor to see if this trial is right for you.